2025-08-26 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, formatted as a concise report.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover, develop, and commercialize novel drugs.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -47.36%
*   **VOO Cumulative Return:** 38.06%
*   **Absolute Difference:** -85.42%
*   **Disparity:** (max: 33.0, min: -90.4, current: -85.9, relative disparity: 3.6)
    *The relative disparity of 3.6 suggests that RXRX's performance is near the lower end of its historical range compared to the S&P 500.*

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2021-2023  | 5.0%    | 73.6%   | -5.0%   | 0.0    | 4.3    |
| 2022-2024  | 0.0%    | 73.6%   | -30.0%  | 0.0    | 2.9    |
| 2023-2025  | 4.0%    | 73.6%   | -40.0%  | 0.0    | 2.1    |

*   **Analysis:** The Alpha values are negative and decreasing, suggesting underperformance relative to the market. Beta is 0.0, which indicating a very low correlation of RXRX's returns to the market. Maximum Drawdown (MDD) is consistently high, indicating significant risk. CAGR is inconsistent and close to zero. Market Cap has declined consistently from 4.3B to 2.1B.

### 2. Recent Price Action

*   **Current Price:** $4.83
*   **Previous Close:** $4.94
*   **Change:** -2.23%
*   **5-Day Moving Average:** 4.882
*   **20-Day Moving Average:** 5.4355
*   **60-Day Moving Average:** 5.3629

*   **Analysis:** The price is below all moving averages, suggesting a downtrend. The 2.23% drop from the previous close is a noteworthy decline.

### 3. Indicators and Signals

*   **Market Risk Indicator (MRI):** 0.3237 (Low Risk)
*   **RSI:** 33.49 (Approaching oversold territory)
*   **PPO:** -1.91 (Below zero, indicating a downtrend)
*   **Hybrid Signal:** Cash_70%_Sell (70% of holdings)
*   **Recent Relative Disparity Change (20-day):** -2.2 (Short-term decline)
*   **Expected Return (%):** -842.8% (Significantly negative, indicating substantial potential underperformance)

*   **Analysis:** The Hybrid Signal suggests a cautious outlook, recommending a high cash position. The negative expected return is a major concern. The MRI is in the low-risk range, but other indicators point to weakness. The recent price drop strengthens the case for caution.

### 4. Recent News & Events

*   **Summary:** Recent news points to volatility, analyst discussions, and major business developments. Investors are advised to monitor news and company announcements.
*   **Implication:** The news suggests significant events are impacting the stock, requiring careful monitoring.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2025-08-05 | -0.4  | 0.01 B$  |

*   **Analysis:** EPS is consistently negative, indicating losses. Revenue fluctuates but is generally low.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.02B  | -5.54%       |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%       |
| 2024-06-30 | $0.01B  | 36.14%       |

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |
| 2024-06-30 | $0.58B   | -16.69%   |

*   **Analysis:**  Revenue is inconsistent. Profit margins are generally negative, particularly in recent quarters. Return on Equity (ROE) is consistently negative, highlighting profitability issues. While equity is generally high, the negative ROE is concerning.

### 7. Overall Assessment

Recursion Pharmaceuticals (RXRX) exhibits significant challenges. Its performance lags significantly behind the S&P 500, with a negative expected return and declining Alpha. Recent price action is bearish, and financial data reveals consistent losses and negative profitability metrics. The Hybrid Signal advises caution, and recent news indicates ongoing volatility.
